



Late-breaking Research Submission Guidelines

Submission Opens on December 10, 2025, and Closes on January 30, 2026

The SCA will be accepting late-breaking research **manuscripts** for the 2026 Annual Meeting in Nashville until January 30, 2026. **Late-breaking research manuscripts should address a timely, important research question and represent science that is anticipated to either change clinical practice or to significantly advance the field of cardiovascular research.**

IMPORTANT INFORMATION

- Submission system **opens on December 10, 2025.**
- Submission system **closes at 11:59 PM (Eastern Time) on January 30, 2026.**
 - Additional submissions will not be accepted after the submission system closes.
 - If you do not receive an email confirmation of your submission within 30 minutes of finalizing your submission, please contact SCA Program Team at nbaus@veritasamc.com.
 - Co-authors must complete their bio and disclosure forms by January 30, 2026.
 - The submission will not be reviewed unless **all** listed authors complete a disclosure form by the deadline.
 - Notifications regarding selection will be sent in early March 2026.

GENERAL REQUIREMENTS FOR SUBMISSION

- Manuscripts must be in English.
- Manuscripts for consideration must have a publication date after May 1, 2026 or are currently under review / in revision at a journal, or in pre-print / in press. Manuscripts on a preprint server that are not yet peer reviewed will also be eligible for consideration.
- The presenting author of the research project must have completed registration for the 2026 SCA meeting and be available in person at the meeting to present their work.
- **Case reports and abstracts are not sufficient for submission in the Late-breaking Research category.**

Evaluation and Outcomes:

- Late-breaking research manuscripts submitted will be screened by a subset of the Scientific Program Committee in consultation with the Research Committee for relevance to the SCA's mission.
- The two (2) or three (3) of the most relevant articles will be presented as a podium presentation during the COR-PM/ Research track program.

INSTRUCTIONS FOR ONLINE SUBMISSION

Submission Content and Format Rules

- Submissions must be in English.
- Titles should be short and specific and should **not** contain abbreviations, quotation marks, or all capital letters.
- Use generic drug/product names rather than trade names.
- Standard abbreviations may be used but should be kept to a minimum.

- Submissions will be accepted in the following file formats: .pdf, doc, or docx.
- Submissions should include the best available evidence and should not include content that is biased or promotional in nature.

General Rules

- **Only manuscripts submitted using the online submission system will be considered.**
- The presenting author must attend the 2026 Annual Meeting in Nashville, TN if the submission is accepted.
- All communication from/to the SCA will be with the presenting author only.
- Submissions are not to be completed by other parties on behalf of the author(s).
- All authors must complete a disclosure of relevant financial relationships at the time of submission.
- Co-authors will receive emailed requests for relevant financial disclosures after the submission has been submitted. If a co-author fails to submit his/her disclosure form, the submission will be disqualified.
 - If there is an extenuating circumstance where an author will be unavailable to submit conflict of interest information, please contact SCA at nbaus@veritasamc.com.
- Once the manuscript is submitted, no revisions are permitted.
- Manuscripts must summarize an original contribution.
 - If there is any question regarding similarity to earlier work or possible duplication, it is the responsibility of the submitting author to contact the SCA at nbaus@veritasamc.com at the time of submission.
- Submitting/presenting author will attest that all co-authors of the submission have granted consent for the material to be submitted for presentation, and that the submitting/presenting author has been granted the right by all co-authors to act on their behalf.
- Submitted text and images must be HIPPA compliant, including masking of all patient identification material. Images with patient identifiers will not be considered for presentation.
- Submitting/presenting author must attest that the research was approved by his/her institution's International Review Board (IRB) and that informed consent/assent was obtained from each subject and/or parent or guardian.
- Institutional quality improvement committee approval is not sufficient without also having IRB approval or a written statement from the IRB that the study is IRB exempt.
- SCA reserves the right to withdraw a submission at any time.
- In the event that a change in presenting author must be made after the submission, the SCA must be notified in writing as soon as possible, email can be sent to nbaus@veritasamc.com.
- Authors will not be provided complimentary registration or any other financial support. Presenting authors are expected to register for and attend the meeting.
- **If a different presenting author must be designated after submission, please adhere to the following:**
 - The presenting author must be a co-author listed on the manuscript at the time of submission. Please notify the SCA at nbaus@veritasamc.com to make this change.
 - Presenter changes made after **February 27, 2026** will not be reflected in any printed or online materials or applications.
 - If a co-author cannot be identified to present the research, the submission must be withdrawn from presentation. Please notify the SCA immediately at nbaus@veritasamc.com.

SUBMISSION REVIEWS

All submissions undergo a blinded peer-review process and will be reviewed on content organization and clarity, relevance to SCA membership, and methodological strength of study design. Submissions should be well written in a style that is understandable to a non-specialist. The “message” should be easily understood by the reader without having to re-read the submission several times.